Nonetheless, the results from TOPARP-B have overall driven the design and conduct of several registration trials of PARP inhibitors in metastatic castration-resistant prostate cancer (NCT02987543, NCT02975934, and NCT03148795), which are likely to guide the clinical use of PARP inhibitors in metastatic prostate cancer in the future. Here, PARP1 is linked to prostate carcinoma.